Agios Pharmaceuticals Sees Stock Surge After Key FDA Approval

Agios Pharmaceuticals shares are trading higher after the U.S. FDA approved AQVESME (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia, marking a significant milestone for the company.